Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 28, 2026Frontiers in ImmunologyOpen Access

Biparatopic targeting of CD38 using CD38-specific trimeric antibody recruiters improves cytotoxicity against multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

HRHenry RischAGAnna Josephine GebhardtNHNiklas Hagen

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Risch et al. (2026) studied this question.

synapsesocial.com/papers/6ab9b4fa7822ec8fc3d8f2bahttps://doi.org/10.3389/fimmu.2026.1915205
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma2025 · 1 citations
  2. 2Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma2025 · 1 citations
  3. 3Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma2024 · 20 citations
  4. 4Lbl-076, a first-in-class GPRC5DxCD38xCD3 trispecific T cell engager (TCE) for the treatment of relapsed/refractory multiple myeloma2025
  5. 5Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity2024 · 8 citations